About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Diabetes and Metabolism Research Group is search is lead by Dr. Rafael Simó (Hirsch index:54), Head of the Endocrinology Department, Professor of Medicine & Endocrinology at UAB and current President of the European Association for the Study of Diabetes-Eye Complications. The group consists of 7 senior clinical investigators, 4 basic post-doctoral researchers, 4 pre-doc researchers, 3 laboratory technicians and one coordinator of clinical assays.
The group belongs to “CIBER” of Diabetes and Associated Metabolic Diseases (CIBERDEM. ISCIII) and has been recognized as consolidated group by the Generalitat de Catalunya (AQU/AGAUR).
Since 2014 this group has been qualified as outstanding in the evaluations performed by the ANEP, CIBERDEM and the external Scientific Advisory Board of VHIR.
The main lines of research are:
IP: Yolima Cossio Gil Collaborators: Alba García Zarzoso, Rafael Simó Canonge, Maria Carmen Baraldés Vallverdú, Joan Carles Peiró Ruiz, Monica Sanchez Bartres, H2O Health Outcomes Observatory, Xavier Serra Ruiz, Marta Ferri Peradalta, Olga Simó Servat, Elena Céspedes Martínez, Ernesto Alejand Lastiri González Funding agency: The Innovative Medicines Initiative Funding: 1097257.5 Reference: H2O_IMI2-2020 Duration: 01/10/2020 - 30/04/2026
IP: Rafael Simó Canonge Collaborators: José García Arumí, Cristina Hernández Pascual, Cristina Pérez Fernández Funding agency: Instituto de Salud Carlos III Funding: 573650 Reference: ICI20/00129 Duration: 01/01/2021 - 31/10/2026
IP: Maria Jose Soler Romeo Collaborators: Alejandra Gabaldon Dominguez, Mario Alonso Narvaez Barros, Pamela Dominguez Baez, Irene Martinez Diaz, Sheila Bermejo Garcia, Alejandra Planas Vilaseca, Concepció Jacobs Cachá, Desentrañando las vías protectoras de los SGLT2i y GLP-1RA en la enfermedad renal diabética: papel de las proteínas adaptadoras Funding agency: Instituto de Salud Carlos III Funding: 122210 Reference: PI21/01292 Duration: 01/01/2022 - 30/06/2026
The families of the professionals had the opportunity to visit the facilities and discover how we work at the institution.
The document provides recommendations for identifying people who are candidates for these treatments and for guiding their implementation and follow-up in clinical practice.
The publications update the pharmacological management guideline for obesity and its complications and present the first European comprehensive management guideline for patients with obesity treated with medications.
